Compare · MO vs NAGE
MO vs NAGE
Side-by-side comparison of Altria Group Inc. (MO) and Niagen Bioscience Inc. (NAGE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MO and NAGE operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- MO is the larger of the two at $123.92B, about 474.4x NAGE ($261.2M).
- Over the past year, MO is up 25.9% and NAGE is down 66.2% - MO leads by 92.1 points.
- NAGE has been more active in the news (11 items in the past 4 weeks vs 2 for MO).
- MO has more recent analyst coverage (20 ratings vs 1 for NAGE).
- Company
- Altria Group Inc.
- Niagen Bioscience Inc.
- Price
- $74.20+1.64%
- $3.27-3.96%
- Market cap
- $123.92B
- $261.2M
- 1M return
- +5.76%
- -4.94%
- 1Y return
- +25.89%
- -66.20%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 2
- 11
- Recent ratings
- 20
- 1
Altria Group Inc.
Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, oral tobacco products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. The company also produces and sells varietal and blended table wines, and sparkling wines under the Chateau Ste. Michelle and 14 Hands names; and imports and markets Antinori, Torres, and Villa Maria Estate wines, as well as Champagne Nicolas Feuillatte in the United States. In addition, it provides finance leasing services primarily in transportation, power generation, real estate, and manufacturing equipment industries. The company sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.
Latest MO
- Altria to Host Webcast of 2026 Second-Quarter and First-Half Results
- UBS reiterated coverage on Altria with a new price target
- SEC Form 11-K filed by Altria Group Inc.
- SEC Form 11-K filed by Altria Group Inc.
- Director Kelly Ennis Debra J sold $418,318 worth of shares (5,790 units at $72.25), decreasing direct ownership by 7% to 73,809 units (SEC Form 4)
- Director Strahlman Ellen R sold $145,118 worth of shares (2,000 units at $72.56), decreasing direct ownership by 7% to 25,102 units (SEC Form 4)
- SEC Form SD filed by Altria Group Inc.
- Amendment: SEC Form 10-K/A filed by Altria Group Inc.
- U.S. Smokeless Tobacco Company Announces Plan to Modernize Manufacturing Footprint Through Facility Relocation
- Altria Group Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Latest NAGE
- Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
- Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
- SEC Form 424B5 filed by Niagen Bioscience Inc.
- SEC Form EFFECT filed by Niagen Bioscience Inc.
- Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
- SVP, General Counsel Lopez Carlos Luis was granted 2,314 shares, increasing direct ownership by 103% to 4,565 units (SEC Form 4)
- Chief Financial Officer Pamir Ozan was granted 4,255 shares, increasing direct ownership by 58% to 11,627 units (SEC Form 4)
- Chief Executive Officer Fried Robert N was granted 1,106 shares, increasing direct ownership by 0.10% to 1,060,087 units (SEC Form 4)
- Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
- Niagen Bioscience Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders